OncoSignal
Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Breast cancer

HR+/HER2-, HER2-low and TNBC: CDK4/6, oral SERDs, PI3K pathway and TROP2 ADCs.

Live from ClinicalTrials.gov and PubMed, fetched 2026-11-11 15:10 UTC. Every row links to its source record.

Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:25 UTC.

Phase advances
11
since 2026-07-14
New Ph2+ trials
33
Results posted
7
Readouts due
22
primary completion reached
Trial papers
40
PubMed, last 60 days
  1. Paper
  2. Paper
  3. New trial
    New Ph1 trial: TRAIN-5 (NCT07928479)

    The Netherlands Cancer Institute. Neoadjuvant Trastuzumab, Pertuzumab and Zongertinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-5 Study

  4. New trial
    New Ph3 trial: ULTRA-B (NCT07928427)

    Fudan University. Comparing Ultrafractionated and Moderate Hypofractionated Radiotherapy for Post-Surgery Breast Cancer

  5. Results posted
    Results posted: EITHICS (NCT04320030)

    [18F]-DPA-714 PET/CT (Positron Emission Tomography/Computerized Tomography) in Triple Negative Breast Cancers

  6. Paper
  7. Paper
  8. Paper
  9. Paper
  10. Paper
  11. Paper
  12. New trial
    New Ph1 trial: NCT07923214

    Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.. A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors

  13. New trial
    New Ph2 trial: NCT07918989

    Memorial Sloan Kettering Cancer Center. A Study of Different Skin Care Approaches to Prevent Skin Reactions in People With Breast Cancer Receiving Radiation Therapy After Mastectomy

  14. New trial
    New Ph2 trial: NCT07918079

    Fudan University. Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy

  15. Results posted
    Results posted: NCT01552434

    Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

  16. New trial
    New Ph3 trial: IMN-Neo (NCT07915739)

    Mahidol University. Internal Mammary Node Irradiation After Neoadjuvant Systemic Therapy for Breast Cancer

  17. Results posted
    Results posted: NCT03104595

    Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer

  18. New trial
    New Ph1 trial: NCT07915297

    Luminance Biosciences Inc. Safety and Biodistribution of [68Ga]Ga DOTA-5G in Subjects With Metastatic Breast Cancer (BC)

  19. New trial
    New Ph2 trial: STEROID-LITE (NCT07914309)

    Washington University School of Medicine. Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer

  20. Results posted
    Results posted: NCT03979508

    Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

  21. New trial
    New Ph2 trial: WISPER (NCT07909889)

    Aarhus University Hospital. Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer

  22. New trial
    New Ph2 trial: NCT07909408

    NYU Langone Health. Psilocybin FCR Early-Stage Breast Cancer

  23. Readout due
    Readout due: NCT05774678 reached primary completion

    M.D. Anderson Cancer Center. Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Tissue Nanomechanical Phenotype Evaluation

  24. Readout due
    Readout due: NCT05550415 reached primary completion

    Universitas Indonesia. The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer

  25. Readout due
    Readout due: NCT01916317 reached primary completion

    Tata Memorial Hospital. Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer

  26. Readout due
    Readout due: NCT04715958 reached primary completion

    Kibo Nam. SHAPE Neoadjuvant Chemotherapy Response

  27. New trial
    New Ph2 trial: NCT07907354

    Yunnan Cancer Hospital. Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer

  28. New trial
    New Ph2 trial: HERBRAIN (NCT07905313)

    Azienda Ospedaliero-Universitaria Careggi. Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)

  29. New trial
    New Ph1 trial: NCT07905001

    Prelude Therapeutics Incorporated. A Phase 1/1b Study of PRT13722 in Participants With Advanced HR+/HER2- Breast Cancer

  30. New trial
    New Ph1 trial: NCT07899892

    Memorial Sloan Kettering Cancer Center. A Study of 68Ga-FAPI Breast PET/MRI Scans in People With Breast Cancer

  31. New trial
    New Ph2 trial: NCT07900516

    The First Affiliated Hospital with Nanjing Medical University. A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.

  32. New trial
    New Ph2 trial: NCT07896668

    Zhejiang Cancer Hospital. Pucotenlimab and Anlotinib in Combination With Chemotherapy

  33. New trial
    New Ph3 trial: PROPHY-SEIN (NCT07898943)

    University Hospital, Clermont-Ferrand. Evaluation of the Effect of Antibiotic Prophylaxis During Lumpectomy for Breast Cancer: Prospective Randomised Double-blind Noninferiority Study of Placebo vs Cefazolin

  34. New trial
    New Ph1/Ph2 trial: NCT07899632

    Medsyn Biopharma, LLC. A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors

  35. New trial
    New Ph1 trial: NCT07897721

    Pfizer. A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors

  36. New trial
    New Ph2 trial: NICBREASTRCT (NCT07897409)

    Universiti Sains Malaysia. The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity

  37. New trial
    New Ph3 trial: NCT07894328

    Jiangsu HengRui Medicine Co., Ltd.. A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer

  38. New trial
    New Ph2 trial: MELODY (NCT07893730)

    University College Cork. Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches

  39. Phase advance
    Pyrotinib advances to Ph3 (indication level)

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University posted NCT07892274: Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer

  40. Phase advance
    Dalpiciclib advances to Ph3 (indication level)

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University posted NCT07892274: Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer

  41. Phase advance
    Trastuzumab Rezetecan advances to Ph3 (indication level)

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University posted NCT07892274: Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer

  42. New trial
    New Ph3 trial: NCT07892274

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer

  43. New trial
    New Ph2 trial: RAPID-NeoBC (NCT07892508)

    Second Affiliated Hospital, Zhejiang University, School of Medicine. Adding Preoperative Radiotherapy Based on Early Treatment Response in Breast Cancer

  44. Phase advance
    Atirmociclib advances to Ph3 (indication level)

    Pfizer posted NCT07890597: A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer

  45. Results posted
    Results posted: NCT03036488

    Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

  46. New trial
    New Ph2 trial: NCT07889115

    Al-Azhar University. Evaluation of the Effect of Amantadine in the Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients

  47. New trial
    New Ph3 trial: NCT07890597

    Pfizer. A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer

  48. New trial
    New Ph1/Ph2 trial: NCT07885683

    Imagion Biosystems, Inc.. MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA)

  49. Results posted
    Results posted: NCT05305365

    Study Assessing QBS72S For Treating Brain Metastases

  50. New trial
    New Ph2 trial: NCT07884201

    Fudan University. Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment

  51. New trial
    New Ph2 trial: EMBRACE (NCT07883512)

    Virginia Commonwealth University. EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction)

  52. New trial
    New Ph3 trial: NCT07879911

    CSPC Megalith Biopharmaceutical Co.,Ltd.. A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer

  53. Results posted
    Results posted: TBCRC042 (NCT02928978)

    Ruxolitinib for Premalignant Breast Disease

  54. Readout due
    Readout due: NCT05852691 reached primary completion

    Hoffmann-La Roche. A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

  55. New trial
    New Ph1 trial: NCT07874880

    MEKanistic Therapeutics, Inc.. MTX-531-001 Phase 1 Study in Advanced Solid Tumors

  56. New trial
    New Ph1 trial: NCT07876596

    Shandong Suncadia Medicine Co., Ltd.. A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080

  57. New trial
    New Ph2 trial: NCT07876557

    Shanghai Junshi Bioscience Co., Ltd.. A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)

  58. Readout due
    Readout due: NCT03377387 reached primary completion

    Memorial Sloan Kettering Cancer Center. Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

  59. Paper
  60. Paper
    Randomized Trial of Hypofractionated Postmastectomy Radiation Therapy in Women With Breast Reconstruction (RT CHARM, Alliance A221505).

    Poppe MM, Le-Rademacher JJ, Haffty BG et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

    Free full text (PubMed Central)View PDFPublisher pageReports NCT03414970
  61. Paper
  62. Readout due
    Readout due: NCT05573555 reached primary completion

    Pfizer. TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

  63. Readout due
    Readout due: NCT04379570 reached primary completion

    Alliance for Clinical Trials in Oncology. Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy

  64. Readout due
    Readout due: NCT05318469 reached primary completion

    Yuan Yuan. Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer

  65. Readout due
    Readout due: NCT04821141 reached primary completion

    University of Kansas Medical Center. Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

  66. Paper
  67. Phase advance
    18F-FDG advances to Ph2 (indication level)

    Peking University Cancer Hospital & Institute posted NCT07848243: Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes

  68. Paper
  69. Readout due
    Readout due: SERCABOT reached primary completion

    Centre Oscar Lambret. Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome

  70. Phase advance
    T-DXd advances to Ph3 (indication level)

    Mario Negri Institute for Pharmacological Research posted MARGARET: Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan

  71. Phase advance
    giredestrant advances to Ph3 in HER2 (segment level)

    Hoffmann-La Roche posted kalitERA: A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment

  72. Phase advance
    Mirvetuximab soravtansine advances to Ph2 (indication level)

    Fudan University posted PROBE: Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer

  73. Paper
  74. Phase advance
    Empagliflozin advances to Ph3 (indication level)

    Tanta University posted NCT07815808: Cardioprotective Effect of Empagliflozin in Breast Cancer Patients

  75. Phase advance
    Metformin advances to Ph3 (indication level)

    Tanta University posted NCT07815808: Cardioprotective Effect of Empagliflozin in Breast Cancer Patients

  76. Readout due
    Readout due: NCT01785420 reached primary completion

    Dr Rajendra A. Badwe. Pre Operative Trastuzumab in Operable Breast Cancer

  77. Readout due
    Readout due: NCT06125522 reached primary completion

    Pfizer. TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

  78. Paper
  79. Readout due
    Readout due: NCT05335473 reached primary completion

    Henan Cancer Hospital. Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

  80. Readout due
    Readout due: NCT04573231 reached primary completion

    University of Wisconsin, Madison. Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

  81. Readout due
    Readout due: NCT06018337 reached primary completion

    DualityBio Inc.. A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

  82. Readout due
    Readout due: NCT06035497 reached primary completion

    Bristol-Myers Squibb. A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

  83. Readout due
    Readout due: NCT07865988 reached primary completion

    Menoufia University. Efficacy of High-Dose Melatonin in Alleviating Radiotherapy-Induced Fatigue in Breast Cancer Patients

  84. Readout due
    Readout due: NCT02954874 reached primary completion

    National Cancer Institute (NCI). Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

  85. Readout due
    Readout due: NCT06568692 reached primary completion

    Processa Pharmaceuticals. A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

  86. Phase advance
    BL-B01D1 advances to Ph3 (indication level)

    Sichuan Baili Pharmaceutical Co., Ltd. posted NCT07729956: A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)

  87. Readout due
    Readout due: NCT05759572 reached primary completion

    Fudan University. Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

  88. Readout due
    Readout due: NCT06144944 reached primary completion

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.